200 related articles for article (PubMed ID: 38668047)
1. High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment.
Vivod G; Merlo S; Kovacevic N
Curr Oncol; 2024 Apr; 31(4):1920-1935. PubMed ID: 38668047
[TBL] [Abstract][Full Text] [Related]
2. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA; Fu L; Goyeneche A; Gao ZH; Telleria C
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813239
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
[TBL] [Abstract][Full Text] [Related]
6. Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety.
Cordeiro CN; Gemignani ML
Obstet Gynecol Surv; 2017 Mar; 72(3):184-193. PubMed ID: 28304416
[TBL] [Abstract][Full Text] [Related]
7. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
[TBL] [Abstract][Full Text] [Related]
8. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
Angarita AM; Cholakian D; Fader AN
Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
[TBL] [Abstract][Full Text] [Related]
9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
10. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA
Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
[TBL] [Abstract][Full Text] [Related]
11. Low-grade serous ovarian cancer: State of the science.
Slomovitz B; Gourley C; Carey MS; Malpica A; Shih IM; Huntsman D; Fader AN; Grisham RN; Schlumbrecht M; Sun CC; Ludemann J; Cooney GA; Coleman R; Sood AK; Mahdi H; Wong KK; Covens A; O'Malley DM; Lecuru F; Cobb LP; Caputo TA; May T; Huang M; Siemon J; Fernández ML; Ray-Coquard I; Gershenson DM
Gynecol Oncol; 2020 Mar; 156(3):715-725. PubMed ID: 31969252
[TBL] [Abstract][Full Text] [Related]
12. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
13. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
14. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
[TBL] [Abstract][Full Text] [Related]
15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
16. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
17. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
18. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
19. [Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum].
Šišovská I; Minář L; Felsinger M; Anton M; Bednaříková M; Hausnerová J; Jandáková E; Weinberger V
Ceska Gynekol; 2017; 82(3):230-236. PubMed ID: 28593778
[TBL] [Abstract][Full Text] [Related]
20. Grading ovarian serous carcinoma using a two-tier system.
Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
